GEN Exclusives

More »

GEN News Highlights

More »
Jan 19, 2010

Fast Forward and JDRF Team Up with Axxam for MS and Diabetes Treatments

  • Fast Forward, the commercial drug-development arm of the National Multiple Sclerosis Society, and the Juvenile Diabetes Research Foundation have entered a partnership with Axxam to develop new treatments for multiple sclerosis (MS) and type 1 diabetes (T1D). Axxam will screen its chemical library to identify compounds that modulate Kv1.3 ion channel activities.

    Recent studies have found that immune cells in MS and T1D contain high levels of the ion channel Kv1.3. Subsequently, the hyperactivity of this channel contributes to the dysfunction of the immune system in MS and T1D.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Ebola Vaccines

When do you think an Ebola vaccine will be available for the general public?